1. Duration of antibiotic therapy for multidrug resistant Pseudomonas aeruginosa pneumonia: is shorter truly better?
- Author
-
Truong CN, Chin-Beckford N, Vega A, DeRonde K, Simon J, Abbo LM, Rosa R, and Vu CA
- Subjects
- Humans, Male, Female, Retrospective Studies, Aged, Middle Aged, Pneumonia, Ventilator-Associated drug therapy, Pneumonia, Ventilator-Associated microbiology, Pneumonia, Ventilator-Associated mortality, Treatment Outcome, Pneumonia, Bacterial drug therapy, Pneumonia, Bacterial microbiology, Pneumonia, Bacterial mortality, Duration of Therapy, Pseudomonas aeruginosa drug effects, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents administration & dosage, Drug Resistance, Multiple, Bacterial, Pseudomonas Infections drug therapy, Pseudomonas Infections microbiology, Pseudomonas Infections mortality
- Abstract
Background: The 2016 IDSA guideline recommends a treatment duration of at least 7 days for hospital-acquired (HAP)/ventilator-associated pneumonia (VAP). The limited literature has demonstrated higher rates of recurrence for non-glucose fermenting gram-negative bacilli with short course therapy, raising the concern of optimal treatment duration for these pathogens. Therefore, we aimed to compare the outcomes for patients receiving shorter therapy treatment (≤ 8 days) versus longer regimen (> 8 days) for the treatment of multidrug resistant (MDR) Pseudomonas pneumonia., Methods: A single-center, retrospective cohort study was conducted to evaluate adult patients receiving an antimicrobial regimen with activity against MDR Pseudomonas aeruginosa in respiratory culture between 2017 and 2020 for a minimum of 6 consecutive days. Exclusion criteria were inmates, those with polymicrobial pneumonia, community-acquired pneumonia, and infections requiring prolonged antibiotic therapy., Results: Of 427 patients with MDR P. aeruginosa respiratory isolates, 85 patients were included. Baseline characteristics were similar among groups with a median age of 65.5 years and median APACHE 2 score of 20. Roughly 75% had ventilator-associated pneumonia. Compared to those who received ≤ 8 days of therapy, no difference was seen for clinical success in patients treated for more than 8 days (80% vs. 65.5%, p = 0.16). The number of 30-day and 90-day in-hospital mortality, 30-days relapse, and other secondary outcomes did not significantly differ among the treatment groups., Conclusions: Prolonging treatment duration beyond 8 days did not improve patient outcomes for MDR P. aeruginosa HAP/VAP., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF